HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Understanding of Informed Consent and Motivators.

Slides:



Advertisements
Similar presentations
IPEC - Fundação Oswaldo Cruz Rio de Janeiro -Brazil Women and Trials in Low and Middle-income settings: the clinical investigators Perspective August 6,
Advertisements

Barriers to Health Service Utilization by Immigrant Families Raising a Child with a Disability Unmet Needs and the Role of Discrimination.
Sponsored by NIH/NIAID/DAIDS Completed Observation of the Randomized Placebo-Controlled Phase of iPrEx with co-funding by the Bill & Melinda Gates Foundation.
EXPLORE (HPTN 015) A Randomized Clinical Trial of a Behavioral Intervention to Prevent Acquisition of HIV Among Men Who Have Sex With Men.
Human Papillomavirus 16: Prevalence, Incidence, and Behavioral Risk Factors Deborah L. Thompson, MD, MSPH March 10, 2004.
1 Prevalence and Correlates of HIV Risk Behaviors of Inmates in a State Prison System Titilayo Abiona, MD, FMCPH Adedeji Adefuye, MD, MPH, FRIPH Joseph.
Presentation Name Recruitment and Accrual of Special Populations Special Population Committee Elizabeth A. Patterson M.D., Chair.
Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
Drug Use and HIV Risk Behaviors among HIV-positive Latino MSM in a Large Urban Setting Jesus Felizzola, MD Mario De La Rosa, PhD Florida International.
© 2013 Denver Health Evaluation of the National HIV Behavioral Surveillance System Among Men Who Have Sex With Men in Denver, Colorado Kathryn DeYoung,
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Syphilis Trends in the United States James D. Heffelfinger, MD, MPH Epidemiology and Surveillance Branch, DSTD Centers for Disease Control and Prevention.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
RISHA IRVIN, MD/MPH SAN FRANCISCO DEPT. OF PUBLIC HEALTH PREVENTION UMBRELLA FOR MSM IN THE AMERICAS (PUMA) Risk Compensation and Pre-Exposure Prophylaxis.
What is a Vaccine? What Is A Vaccine? A vaccine is a substance that teaches the body’s immune system to recognize and protect against a disease caused.
C. Andres Bedoya, PhD Behavioral Medicine Service Department of Psychiatry Massachusetts General Hospital / Harvard Medical School Factors related to high-risk.
Clinical Trials Medical Interventions
1 Using Biostatistics to Evaluate Vaccines and Medical Tests Holly Janes Fred Hutchinson Cancer Research Center.
Sexual Risk Behaviors of Self- identified and Behaviorally Bisexual HIV+ Men. By: Matt G. Mutchler, PhD; Miguel Chion, MD, MPH; Nancy Wongvipat, MPH; Lee.
Enrollment of Women and Racial Minorities in Clinical Trials for Diabetes Medications Ellen Pinnow 1, Pellavi Sharma 1, Ameeta Parekh 1, Kimberly Thomas.
What predicts participation in community based HIV prevention programs for MSM? David M. Huebner, PhD, MPH Rae Jean Proescholdbell, PhD Diana Formoso,
THE ROLE OF RELATIONSHIP STATUS ON HIV TESTING AMONG AFRICAN AMERICANS Alexandra Marshall, PhD, MPH, CPH, CHES Duston Morris, PhD, MS, CHES.
HIV/STD Epidemiology in Oklahoma HIV/STD Service Division of Prevention and Preparedness Oklahoma State Department of Health.
EPID Introduction to Analysis and Interpretation of HIV/STD Data Introduction: STDs and HIV—a brief background Manya Magnus, Ph.D. Summer 2001.
HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Mental Health and Substance Use Problems among.
Assessing Minority Participation in Clinical Trials: Setting Attainable Goals The Minority and Women Clinical Trials Recruitment Program Department of.
Oguogho Cletus. “We do not believe in all those kind of disease here, we have heard about it, but it could be spiritual sickness they call AIDS in the.
Stuart Michaels, Academic Research Centers, NORC Sexual Behavior & Sexual Identity among Men who have Sex with Men (MSM)
Design of Phase III Microbicide Trials: Choice of Control Group August 20, 2003 Rosalie Dominik, DrPH Director of Biostatistics Institute for Family Health.
The NIDCR funded Collaborating Research Centers to Reduce Oral Health Disparities (CRCROHD) represent an innovative approach to understanding determinants.
The French National Agency for Research on Aids and Viral Hepatitis – Clinical Research Legislation: A French Experience Ingrid Callies Legal Counsel in.
HIV/AIDS VACCINE AWARENESS Vaccine 101 Jeremiah Brewer Health and Training Educator African – Americans Reach and Teach Health Ministry.
Background Study Objectives Poster No. B50 Track 2  Family planning affects women’s health and lives, and depends on a variety of socio-demographic and.
HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University USE OF A RAPID HIV HOME TEST TO SCREEN POTENTIAL.
RSPH of Emory University Controlling our Bodies: Social Inequality and Risk for HIV Infection among Black Women Kimberly R. Jacob Arriola, Ph.D., MPH APHA.
VIDI SYMPOSIUM Criteria Influencing Potential Impact of HIV Prevention Interventions January 14, 2008 Thomas Fleming, PhD University of Washington Fred.
Health Psychology Lecture 8 Chronic Illness and AIDS.
Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,
How willing are gay men to “cut off” the epidemic? Circumcision among MSM in the Andean region Guanira J 1, Lama JR 1, Goicochea P 1, Segura P 1, Montoya.
Funded by NIDDK RO1 DK53942 Women’s Use of the Internet for Health Information: The Impact of Selected Demographic and Health Variables Mary L. Klem, PhD,
Cynthia Gomez, Olga Grinstead, Dellanira Valencia-Garcia, Debra Allen, Dina Hondrogen, Angelica Martinez, Kathleen Erwin University of California San Francisco,
Co-infections of Hepatitis C or Tuberculosis Among Persons Living with HIV in The Florida Cohort Project Alexander Zirulnik MPH, Chukwuemeka Okafor MPH,
The Continuum of Participation in Research From HIV Prevention to Care: Seven Years of the iPrEx Trial Public Engagement with HIV Science.
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
Stephen Nkansah-Amankra, PhD, MPH, MA 1, Abdoulaye Diedhiou, MD, PHD, H.L.K. Agbanu, MPhil, Curtis Harrod, MPH, Ashish Dhawan, MD, MSPH 1 University of.
HIV in America What’s New in 2012 Christopher Hurt, MD Clinical Assistant Professor NC AIDS Education and Training Center 2012 HIV Update.
Re-Emerging HIV Epidemics among MSM in the United States and Other Industrialized Nations Ron Stall, Thomas C. Mills and Michael Marshal University of.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2013.
| Web: The findings and conclusions in this report are those of the authors and do not necessarily represent the official.
Jan Risser, Paige Padgett, Jane Richards (UT SPH) Hafeez Rehman, Marcia Wolverton (HDHHS)
Still a Hard-to-Reach Population? Using Social Media to Recruit Latino Gay Couples for an HIV/STI Prevention Intervention Adaptation Study Omar Martinez,
HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.
Guanira J1, Lama JR1, Goicochea P1, Segura P1, Montoya O2, Sánchez J1
Regulatory Considerations for Approval: FDA perspective
HIV Infection in Women in Our Community: The Continuum of Care
Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.
On behalf of The MTN-020/ASPIRE Study Team
Clinical Trials Medical Interventions
Cedric Whitfield, MPH, CHES
Table 1: NHBS HET3 Participant Characteristics
Clinical Trials.
PrEP introduction for Adolescent Girls and Young Women
Tearing Down Fences HIV/STD Prevention in Rural America
African perspective on ethical guidelines Salim S Abdool Karim
African American.
Unmet Needs and the Role of Discrimination
PrEP.
Florida International University
Presentation transcript:

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Understanding of Informed Consent and Motivators for Participation Among MSM HIV Vaccine Trial Participants Lisa Chin, JD, EdD, MPH, MA HIV Center Grand Rounds June 30, 2011

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Why do people participate in HIV vaccine trials (HVT) and do they know what they are getting into?

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Background HIV Vaccine Development  HIV vaccines are critical for comprehensive prevention strategy against HIV/AIDS  Human subject testing is essential aspect of HIV vaccine development

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Recruitment Issues in HVTs  Many participants are needed to ensure power to assess a vaccine’s safety and efficacy  Willingness to participate in a HVT varied from 22% to 79%  In practice only 20% of participants actually enrolled (Buchbinder et al., 2004)  Understanding motivations to participate can help to improve recruitment

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Understanding of HVT Informed Consent Information Ethical implications for informed consent o Concerns about therapeutic misconception Most studies among non-HVT study populations o Vaccine preparedness o Vaccine feasibility o Longitudinal epidemiological Few studies with actual HVT participants o South African HVT o US IDU HVT participants o North American HVT – vaccine efficacy

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Pilot Study  Qualitative Study with high- and low-risk participants in HVT  Formative Research for Quantitative Instrument Development  Quantitative Assessment with HVT Participants

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Qualitative Part of Pilot Study Domains of interest: Understanding of HVT informed consent information Perceptions of HVT informed consent process Potential therapeutic misconception Motivators for participating Study participants: High-risk individuals HVT participants (20 MSMs) Low-risk individuals HVT participants (20 women & men)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Parent HVT for Pilot Study  Phase II Trial -- Double Blind Vaccine vs. Placebo  Study aims are to assess: Vaccine safety and immunogenicity Reduction of viral load upon HIV acquisition  Vaccines not made from HIV virus  Recruited from 2 research sites in NYC

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Demographics  Age range: yrs (mean = 35.8)  Ethnicity 7 White 10 African-American 1 Hispanic 1 Asian 1 Mixed  Education (Highest Level) 1 <HS 11 HS degrees 6 BA degrees 2 MA degrees

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Qualitative Probes Motivators for participation Decision to get involved Other factors involved Family or friends who are healthcare professionals Role of payment Role of HIV concerns Understanding of informed consent Study goals What study involves Possible risks and benefits Inputs/pressure to participate

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Study Analysis Qualitative interviews 1-2 hour interviews Transcribed and Coded 2 Coders Coding themes Understanding/misunderstanding-misconception of HVT o Study purpose/goals o Study design o Vaccine and placebo Perspectives on risks and benefits of participation Understanding of voluntariness of participation Motivators for participation o Sources for motivations o Role of compensation as a motivator

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Motivators for Enrolling into and Staying in Study Altruism Compensation

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Altruistic Motives from Various Sources Familial: Values taught that helping others is important Cultural/Community: Emphasis on giving back to the community or the desire to help Religious: Personal religious values/beliefs opposing observed hypocrisy Experiential: Personal experiences with HIV/AIDS Professional: Being a healthcare professional or having family members who are Political: Activism in response to the HIV/AIDS epidemic Moral: Making up for past wrongs Existential: Provides a sense of meaning and purpose Psychological: Obtaining gratification

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Altruistic Motives Emphasis giving back to the community or the desire to help the community I am helping my community, as far as gay men, black gay men…the community I live in. (AA, age 41) Obtaining gratification It’s very fulfilling for me. I’m very proud of being in this. (W, age 23)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Compensation as a Motivator  Sole motivator (n=1)  Important but not sole motivator (n=4)  Added bonus but not motivator (n=5)  Compensation not a motivator (n=10)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Compensation Important but not Sole Motivator At the beginning, it was pretty much for extra cash. But I chose this particular study because my parents have had friends that had HIV. It’s pretty much a win- win. Win-win as in I would be doing something that I support and I would make a few extra bucks from it. (AA, age 23) I’m unemployed. I need the money. I’m not going to lie about that. And the same thing is I know a lot of people with HIV. (AA, age 39)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Compensation as an Added Bonus To maintain follow-up visits/adherence I probably would have done it for free, but that definitely gets [you] to the appointment. (AA, age 28) It motivates you to show up on time. If you feel like you’re not getting paid, you can start taking liberties with the responsibilities that you have. (W, age 43) Acknowledgement of participant’s time The amount of money that I end up getting from this study is not even really pocket change. It definitely does make me feel that my time is valuable at least. (W, age 23)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Compensation not a Factor I’ve probably would’ve still participated even they weren’t paying me. (W, age 27) I didn’t even know you got paid for it, so that wasn’t a factor…Just the fact I wanted to help. (W, age 28)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Understanding of Informed Consent (1)  Participants had basic understanding of HVT  Several misunderstandings/misconceptions about study elements and concepts Study purpose o Many said “cure” or “prevent HIV acquisition”, not decrease viral load or examine vaccine safety Process of randomization o What worked best for the participant I think the doctors after they look at my file, they found out what was best after they did all the blood work and all that. (AA, age 44) o Based on participant’s behavior I think it’s based on what you’re going in and telling them. It has to be based on some type of activity. (AA, age 39)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Understanding of Informed Consent (2) Some confusion about role of placebo It prevents people from changing behavior or lying about or overstating symptoms. [Participants] also lie about their symptoms. Like, are you really going to have nausea off a placebo? It’s to keep people honest. If I’m deciding not to be honest and say, “I’m feeling nauseous”, [the staff] will say, “Hold on, something’s up because you’re just taking a placebo.” So, it’s pretty much just to keep people honest. (AA, age 23)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Interpretation of HVT Concepts Randomization o Interpreted literally as a “coin toss” (i.e., an actual coin was used Do y’all toss a coin and decide which shot you’re going to give me? (AA, age 42) What is in the vaccine o Synthetic HIV = “fake HIV” o “Crippling” actual HIV virus How the vaccine works o Taking a snapshot of virus or antibodies of virus…It’s kind of like a security guard having a picture of a wanted man. If that wanted man comes to the building, he knows. (AA, age 23)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Summary  Various motives for participation  Altruism is a multi-dimensional phenomena (instead of single dimension)  Compensation appears not to be the sole motivator for HVT participation  Overall basic understanding of HVT  Some difficulties in understanding more technical elements/components of HVT (e.g., randomization, placebo, vaccine)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Implications Use of altruism as a marketing strategy for HVT recruitment Strategies are needed to help participants better understand components of HVT Simplify written patient education materials about HVT Use of multi-media technology as an educational tool Review informed consent information with participants at various points of HVT trial

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Study Limitations  Study population limited to MSM: Motivations with other populations may differ  Participants interviewed after enrollment: Issue of recall bias  Participants interviewed only once: Views on motivation may change over time

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Future Research Among different populations and with larger samples, future studies can examine: Frequencies of types of altruism and possible associations with entrance and retention into study, and adherence to protocol The role and importance of study compensation as a motivator (weighing of altruistic benefits against compensation) Frequencies of types of misunderstandings and predictors (education, other socio-demographic variables, cultural factors and beliefs) Effects of types of misunderstandings on entrance and retention into study, and adherence to protocol

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Acknowledgments  Robert Klitzman, MD, Scientific Mentor  HIV Center Pilot Studies Program (Pat Warne, PhD)  HIV Center (PI: Anke Ehrhardt, PhD)  HIV Center Ethics and Policy Core, Development Core, IRMC, and HIV Center Administration  HIV Center T32 Postdoctoral Training Fellowship Program (PI: Theo Sandfort, PhD)  Scott Hammer, MD, and CUMC HIV Vaccine Trial Clinic and Beryl Koblin, PhD, and New York Blood Center Project Achieve  Jacqueline Berenson, MD (Clinical Forensic Psychiatry Program, NYSPI/CU)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Thank you

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Altruistic Motives Familial – family values taught that helping others is important It’s really important that everybody does something to give back to the community, which is something my mother instilled in me. (W, age 27) Professional – Being a healthcare professional or having family members who are healthcare professional I think [family members who are healthcare professionals] learn a lot from studies like this, a lot about diseases and how to prevent them, like how to find cures. (Asian, age 32)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Altruistic Motives Religious values/beliefs opposing observed hypocrisy I was a closeted person. I was raised Italian Catholic. There was a lot shame around that. And I have a lot resentment toward the Catholic Church how they treat the LGBTQ community… So it’s very personal to me. It’s not about me or my future, but more about the future of the next generation to follow, if I can help out in any way. (W, age 45)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Altruistic Motives Existential, providing a sense of meaning and purpose I wanted to be part of something that’s going to help. Be part of something that we need. Part of something that could help cure millions of people. (AA, age 44)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Altruistic Motives Moral – Making up for past wrongs I did too much wrong, and if I could give back to the community, I did my part. (AA, age 44)

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Participants’ Altruistic Motives Personal experiences with HIV/AIDS I chose that particular study because my parents have had friends that had HIV. I’ve been around it. (AA, age 23) Political activism in response to the HIV/AIDS epidemic I started working more formally in [HIV/AIDS outreach], trying to educate people, and just helping out people…participating in [the HIV vaccine trial] was like a next step… Somebody has to do it. (AA, age 28)